Unibest

Pharmaceutical intermediates

Regorafenib Intermediates

1 pharmaceutical intermediate for Regorafenib. Indication: Gastrointestinal stromal tumor; Hepatocellular carcinoma; Colorectal cancer.

提交项目All intermediates

About Regorafenib

Originator
Bayer Healthcare Pharmaceuticals Inc
Indication
Gastrointestinal stromal tumor; Hepatocellular carcinoma; Colorectal cancer
Approved Date
09/27/2012
DS/DP
06/02/2030

Available intermediates

1 intermediate currently listed for Regorafenib. Request specifications, documentation or a quotation for any item below.

Regorafenib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Amino-3-fluorophenol399-95-1//

Other programs under R

Ramelteon RelugolixRemdesivir RemibrutinibRepotrectinibResmetiromRevumenibRibociclib Succinate

Building toward Regorafenib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →